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Perfluoroalkyl substances (PFAS) are persistent and ubiquitous environmental contaminants, and human expo-
sure to these substances may be related to preeclampsia, a common pregnancy complication. Previous studies
have found serum concentrations of PFAS to be positively associated with pregnancy-induced hypertension and
preeclampsia in a population with high levels of exposure to perfluorooctanoate. Whether this association exists
among pregnant women with background levels of PFAS exposure is unknown. Using data from the Norwegian
Mother and Child Cohort Study conducted by the Norwegian Institute of Public Health, we carried out a study of
nulliparous pregnant women enrolled in 2003–2007 (466 cases, 510 noncases) to estimate associations between
PFAS concentrations and an independently validated diagnosis of preeclampsia. Wemeasured levels of 9 PFAS in
maternal plasma extracted midpregnancy; statistical analyses were restricted to 7 PFAS that were quantifiable in
more than 50% of samples. In proportional hazards models adjusted for maternal age, prepregnancy body mass
index (weight (kg)/height (m)2), educational level, and smoking status, we observed no strongly positive associa-
tions between PFAS levels and preeclampsia. We found an inverse association between preeclampsia and the
highest quartile of perfluoroundecanoic acid concentration relative to the lowest quartile (hazard ratio = 0.55,
95% confidence interval: 0.38, 0.81). Overall, our findings do not support an increased risk of preeclampsia
among nulliparous Norwegian women with background levels of PFAS exposure.
Norwegian Mother and Child Cohort Study; perfluoroalkyl substances; perfluorooctanoic acid; perfluorooctane
sulfonate; perfluoroundecanoic acid; preeclampsia
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LOQ, limit of quantification; MBRN, Medical Birth Registry of
Norway; MoBa, The Norwegian Mother and Child Cohort Study; PFAS, perfluoroalkyl substance; PFDA, perfluorodecanoic acid;
PFHpS, perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic
acid; PFOS, perfluorooctane sulfonate; PFUnDA, perfluoroundecanoic acid.
Preeclampsia is a serious complication of pregnancy that
consists of new-onset hypertension combined with kidney
dysfunction, which frequently leads to preterm delivery. Pre-
eclampsia affects approximately 3% of pregnancies in the
United States (1) and in Norway (2), and it is a leading cause
of maternal morbidity and mortality. The cause of preeclamp-
sia remains obscure, but it is likely multifactorial, with both
genetic and environmental contributions. Risk factors for
preeclampsia include nulliparity, personal or family history
of preeclampsia, hypertension, diabetes, autoimmune disor-
ders, kidney disease, obesity, multiple gestation, history of
subfertility, long interval between pregnancies (3), and ad-
vanced maternal age (4, 5). Cigarette smoking during preg-
nancy is associated with an estimated 30% reduction in risk
(6). Exposure to certain environmental contaminants may in-
crease a woman’s risk of developing preeclampsia (7, 8).
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Perfluoroalkyl substances (PFAS) are persistent chemicals
that have been detected in blood samples from numerous
human populations worldwide (9–12). The most commonly
measured PFAS, perfluorooctane sulfonate (PFOS) and
perfluorooctanoic acid (PFOA), have been used in industrial
and consumer products, such as surface treatments for car-
pets and fabrics, food packaging, and fire-fighting foam
(13). In non-occupationally exposed populations, ingestion
of PFAS in food is believed to be the principal source of ex-
posure (14–16). Other pathways of PFAS exposure may in-
clude drinking water (17), breast milk (18), and house dust
(16). PFAS are highly stable and resist metabolism or degra-
dation (9, 19). In human serum, the elimination half-lives are
estimated to be 4.8 years for PFOS and 2.3 years for PFOA
(20, 21).
Despite the ubiquitous presence of PFAS in humans, the
potential for adverse health effects resulting from chronic,
low-level exposure has not been adequately studied, par-
ticularly among pregnant women. A recent study of non-
occupationally exposed women living in an area of high
PFOA contamination in drinking water found PFOA and
PFOS to be positively associated with preeclampsia (22).
The possibility that exposure to these widespread environ-
mental contaminants during pregnancy may increase the risk
of preeclampsia is of substantial public health concern and
merits further examination. We explored this question in a
case-cohort study of women with background levels of expo-




This is a substudy within MoBa, a prospective pregnancy
cohort study conducted by the Norwegian Institute of Public
Health (23–25). The study was approved by the Regional
Committee for Medical Research Ethics and the Norwegian
Data Inspectorate. Participants were recruited from through-
out Norway in 1999–2008. Pregnant women who scheduled
a routine ultrasound examination between 17 and 20 weeks of
gestation were invited by mail to participate in the study, and
39% of invited women participated. Informed consent was
obtained from each MoBa participant upon recruitment.
Data were linked to the Medical Birth Registry of Norway
(MBRN) (26). Further details may be found at www.fhi.no/
morogbarn. The present study is based on version 4.301 of
the quality-assured data files released for research.
Eligibility requirements for this analysis were pregnancy
with a singleton infant, no previous live births or stillbirths,
no chronic hypertension before pregnancy, a midpregnancy
plasma sample preserved in ethylenediaminetetraacetic acid,
and enrollment in MoBa in 2003–2007. We restricted the
study to women with no previous live births or stillbirths
because PFAS have been shown to decline with recent preg-
nancy and lactation (27) and because nulliparous women
may have different risk factors for preeclampsia than women
with previous pregnancies (3, 28). We restricted eligibility
to women who enrolled in 2003 or later because the lab-
oratory analysis of PFAS required ethylenediaminetetra-
acetic acid anticoagulation, a process initiated in MoBa in
2003.
From 549 eligible cases of validated preeclampsia in this
time frame, 500 were randomly selected for the study. From
approximately 21,500 eligible pregnancies, 567 were se-
lected at random as the subcohort sample, 17 of whom were
also validated cases. Three of the original subcohort members
reported chronic hypertension to the MBRN and were ex-
cluded from the present analysis. One member of the subco-
hort had a gestational age at delivery reported to the MBRN
of less than 20 weeks and thus was excluded because she was
never at risk to develop preeclampsia. We were missing data
for each modeled covariate for less than 6% of participants.
Exposure
Maternal nonfasting blood samples were collected at hos-
pitals and maternity units across Norway at study enrollment.
Samples were shipped at ambient temperature to the MoBa
biorepository in Oslo, Norway, where plasma was separated,
aliquoted, and stored at −80°C. The majority of the samples
were received and processed the day after collection (25).
PFAS are chemically stable (29), and therefore changes in
plasma concentrations during shipping were expected to be
minimal. A recent study found no change in concentrations
of 4 PFAS in serum during 10 days of storage at room tem-
perature (30).
Concentrations of 9 PFAS were measured in maternal
plasma using high-performance liquid chromatography/
tandem mass spectrometry at the Norwegian Institute of Pub-
lic Health. Additional details of the analytic process have
been published previously (31). Statistical analyses were
limited to PFAS that were quantifiable in greater than 50%
of the samples: PFOS, perfluoroheptane sulfonate (PFHpS),
perfluorohexane sulfonate (PFHxS), PFOA, perfluorononanoic
acid (PFNA), perfluorodecanoic acid (PFDA), and perfluoro-
undecanoic acid (PFUnDA). The limit of quantification
(LOQ) was 0.05 ng/mL for these 7 PFAS. The total area of
linear and branched isomers was integrated for quantification
of PFOS. A total of 25 blinded specimens from a single pool
were analyzed in batches with the sample specimens for qual-
ity assurance and quality control purposes.
Outcome
At the time of delivery, birth attendants reported the pres-
ence of preeclampsia to the MBRN using a standard form. A
validation study was conducted to quantify the performance
of the MBRN in identifying preeclampsia (K.K., unpub-
lished data, 2014). Antenatal medical records were reviewed
for evidence of meeting the diagnostic criteria for preeclamp-
sia published by the American College of Obstetricians and
Gynecologists (32). Validated preeclampsia in our study re-
quired evidence of both of the following at the same antenatal
clinic visit: 1) systolic blood pressure of at least 140 mm Hg
or diastolic blood pressure of at least 90 mmHg that occurred
after 20 completed weeks of gestation and 2) proteinuria, de-
fined as a urine dipstick measurement of at least 1+.
Our definition differs from that of the American College of
Obstetricians and Gynecologists in that we relied on a single
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urine dipstick measurement, whereas their definition recom-
mends the use of a 24-hour urine collection to diagnose
proteinuria. The results of 24-hour urine collection were gen-
erally not available to us in antenatal records. Additionally,
our definition required that hypertension and proteinuria be
documented at the same clinic visit. The gestational week
of the clinic visit during which these diagnostic criteria
were met was recorded. Gestational age was estimated by
the attending midwife based on a combination of ultrasound
and last menstrual period dates.
Although the MBRN validation study (K.K., unpublished
data, 2014) also considered hospital discharge diagnoses of
preeclampsia, our study excluded cases that could not be con-
firmed using the antenatal medical record. Antenatal medical
records from a sample of MoBa participants with no pre-
eclampsia reported to the MBRN were also examined in
the independent validation study; however, in the random
subcohort from the larger MoBa population, the noncase sta-
tus was not independently validated. On the basis of the val-
idation study, we estimated that the negative predictive value
of having no preeclampsia reported to the MBRN was ap-
proximately 95%.
We excluded both cases and cohort members with evidence
of chronic hypertension because diagnosis of preeclampsia
in the presence of chronic hypertension is clinically compli-
cated and often ambiguous (33). Chronic hypertension was
defined as any of the following: 1) hypertension reported to
theMBRN or on theMoBa questionnaire, 2) an International
Classification of Diseases, 10th Revision code corresponding
to chronic hypertension on the antenatal medical chart, or
3) systolic blood pressure of at least 140 mm Hg or diastolic
blood pressure of at least 90 mm Hg diastolic before 20
weeks of gestation documented on the antenatal medical
chart.
Other variables
At the time of enrollment inMoBa, women provided infor-
mation via questionnaire regarding a number of demographic
and lifestyle characteristics and events in their reproductive
and medical history. Covariate information was obtained as
follows: maternal age at delivery was reported to the MBRN;
prepregnancy body mass index (BMI) was calculated as the
participant’s self-reported prepregnancy weight in kilograms
divided by height in meters squared; maternal educational
level was self-reported in response to a questionnaire item re-
questing the highest level of education completed; and mater-
nal smoking during pregnancy was self-reported in response
to the question, “Do you smoke now (after you became preg-
nant)?” at a median of 18 weeks gestation.
Creatinine and cystatin C were measured in midpregnancy
plasma samples to evaluate whether changes in kidney func-
tion and glomerular filtration rate could be detected. High-
density lipoprotein (HDL) cholesterol was measured in the
same nonfasting plasma sample. All 3 analytes were mea-
sured at the National Institute of Environmental Health
Sciences using an Olympus AU400e chemistry immuno-
analyzer (Olympus America, Center Valley, Pennsylvania).
The procedure used to measure creatinine was a kinetic mod-
ification of the Jaffe procedure (34), in which creatinine reacts
with picric acid at an alkaline pH. The cystatin C assay was
based on the sol particle immunoassay (35), using colloidal
gold particles coated with anti-cystatin C–specific polyclonal
antibodies. HDL concentration was measured using reagents
from Beckman Coulter (Brea, California).
Statistical analysis
We used weighted Cox proportional hazards models to es-
timate hazard ratios and 95% confidence intervals by quartile
of plasma concentration of each PFAS. Weights were based
on the inverse probability of selection into the case-cohort
study (36). The outcome was validated preeclampsia, and
the event time was the gestational week at which the parti-
cipant met the diagnostic criteria. Modeled covariates were
selected based on a directed acyclic graph representing
associations reported in the literature. The minimally suffi-
cient adjustment set was identified using DAGitty, version
1.0 (www.dagitty.net). The modeled covariates and their cat-
egorizations were: maternal age at delivery (continuous); pre-
pregnancy BMI (continuous); maternal educational level
(≤12, 13–16, >16 years); and smoking at midpregnancy
(yes or no). Additional analyses were conducted with separate
models adjusted for plasma creatinine, cystatin C, or HDL
cholesterol, with each modeled as a continuous variable.
Concentrations of PFAS were analyzed in 2 ways: 1) in
quartiles, with the lowest quartile serving as the reference cat-
egory (except for PFDA, which was categorized as at or above
versus below the median because more than 25% of values
were below the LOQ) and 2) as natural-log–transformed con-
tinuous variables to assess linear trends. Values below the LOQ
were replaced by a single value equal to the expected value of
the log-normal distribution, given that the value was below the
LOQ; this was calculated as the mean of values below the LOQ
randomly drawn from the estimated log-normal distribution
(37). The proportional hazards assumption was evaluated
through regression and graphical inspection of the weighted
Schoenfeld residuals plotted against time.
We examined the shape of the dose-response function
using logistic regression models of the association between
each continuous PFAS exposure, modeled as a restricted
cubic spline function with 5 knots at the 5th, 25th, 50th,
75th, and 95th percentiles (or, in the case of PFDA, with 4
knots at the 25th, 50th, 75th, and 95th percentiles), and pre-
eclampsia as a binary outcome. All statistical analyses were
performed using SAS, version 9.3 (SAS Institute, Inc., Cary,
North Carolina). The logistic spline models were fitted using
a SAS macro created by Desquilbet and Mariotti (38).
RESULTS
The present analysis included 976 nulliparous women
(466 cases and 510 noncases) for whom we had complete in-
formation on modeled covariates. The participants ranged in
age from 16 years to 44 years (Table 1). There were no nota-
ble differences in age distributions between cases and non-
cases. BMI ranged from 15.4 to 48.8, and there were more
cases than noncases with a BMI of 30 or greater (16% of
cases vs. 7% of noncases). The majority of participants had
13–16years of education (75%of cases and70%ofnoncases).
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Overall, 7% of participants reported current smoking during
pregnancy, with a slightly lower prevalence among cases
(6%). The median duration of pregnancy was shorter among
cases (274 days) than noncases (282 days), and 21% of cases
had pregnancies shorter than 37 weeks of gestation, com-
pared with less than 5% of noncases.
Of the 7 PFAS quantifiable in plasma samples from more
than 50% of participants (Table 2), PFOS had the highest me-
dian concentration (12.87 ng/mL), and it was quantifiable in
100% of samples. PFOA had the second highest median con-
centration (2.78 ng/mL), and it was also quantifiable in 100%
of samples. The other measured PFAS in descending order
of median concentration were PFHxS, PFNA, PFUnDA,
PFHpS, and PFDA. PFDA was quantifiable in 71% of sam-
ples. Interassay coefficients of variation ranged from 9% for
PFOA to 30% for PFHpS (Table 2). The PFAS were moder-
ately to highly correlatedwith one another (Table 3). The low-
est correlation observed was between PFDA and PFHpS
(rs = 0.18), and the highest was between PFNA and PFDA
(rs = 0.75). PFOS and PFOA were correlated at rs = 0.64.
None of the 7 PFAS had strongly positive associations
with preeclampsia, either in quartile analyses or when
PFAS were entered as continuous natural-log–transformed
variables (Table 4). Certain quartiles of PFHpS and PFOS
had weakly positive associations with preeclampsia. Interest-
ingly, there was an inverse association between PFUnDA and
preeclampsia; the highest quartile of PFUnDA had an ad-
justed hazard ratio of 0.55 (95% confidence interval: 0.38,
0.81) relative to the lowest quartile, and each increase of 1
ln-ng/mL of PFUnDA was associated with an adjusted haz-
ard ratio of 0.78 (95% confidence interval: 0.66, 0.92). Addi-
tional adjustment for plasma creatinine or plasma cystatin C
did not produce meaningful changes in any effect estimates
(results not shown). Additional adjustment of the PFUnDA
models for HDL also did not produce meaningful changes
in the effect estimates (results not shown).
The shape of the dose-response function was characterized
using restricted cubic spline functions for the association
between each continuous PFAS exposure variable and pre-
eclampsia (Figure 1). The spline graphs suggested weakly in-
verse associations of PFNA (Figure 1B), PFDA (Figure 1C),
andPFUnDA (Figure 1D)with preeclampsia. Therewas some
indication in the spline graphs of an increase in preeclampsia
risk at the higher concentrations of PFHpS (Figure 1F) and
Table 1. Characteristics of Subjects in a Subcohort of the Norwegian
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Table 2. PlasmaConcentrations of 7 Perfluoroalkyl Substancesa in Subjects in a Subcohort of theNorwegianMother









Plasma Concentration (ng/mL) by Percentile
5th 25th 50th 75th 95th CVc
Perfluorooctanoic acid PFOA 100.0 7 1.43 2.14 2.78 3.57 5.15 8.6
Perfluorononanoic acid PFNA 99.7 8 0.24 0.39 0.54 0.74 1.12 13.3
Perfluorodecanoic acid PFDA 71.1 9 <LOQ <LOQ 0.10 0.18 0.34 27.0
Perfluoroundecanoic acid PFUnDA 83.7 10 <LOQ 0.08 0.17 0.27 0.47 22.2
Perfluorohexane sulfonate PFHxS 99.5 6 0.27 0.49 0.69 0.95 1.78 14.6
Perfluoroheptane sulfonate PFHpS 83.6 7 <LOQ 0.09 0.15 0.23 0.37 29.8
Perfluorooctane sulfonate PFOS 100.0 8 6.07 9.69 12.87 17.03 25.53 11.4
Abbreviations: CV, coefficient of variation; LOQ, limit of quantification.
a The 7 perfluoroalkyl substances were those with concentrations that could be quantitated in more than 50% of
samples.
b Refers to the number of carbons in the fully-fluorinated alkyl chain.
c Interassay coefficient of variation was calculated as (standard deviation/mean) × 100 for 25 pooled samples.
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perhaps PFOS (Figure 1G). Overall, the results of the logistic
regression analysis using restricted cubic spline functions ap-
peared to parallel the results of the Cox proportional hazards
models (Table 4).
DISCUSSION
In the present study of plasma PFAS concentrations and
preeclampsia among 976 nulliparous Norwegian women
with background levels of exposure, we observed 1 inverse
association (PFUnDA) and 2 weakly positive associations
(PFHpS and PFOS). A series of related studies on pregnancy-
induced hypertension and preeclampsia conducted in a pop-
ulation exposed to PFOA-contaminated drinking water
reported positive associations with both PFOA and PFOS
(22, 39). The difference between the results of our study
and those of previous studies may be partly attributed to dif-
ferences in exposure assessment, differences in preeclampsia
case definition, or the restriction of our study to nulliparous
women.
Our study directly measured PFAS at midpregnancy, be-
fore the onset of preeclampsia, whereas previous studies used
indirect methods to assess PFAS during pregnancy. Specifi-
cally, one study used predictive modeling to assign exposure
at the time of pregnancy (39); another measured exposure
concentration in serum up to 5 years after the pregnancy of
interest (22). Exposures assessed differently could be biased
by different unmeasured factors.
The PFOA concentrations measured or predicted in previ-
ous studies were substantially higher than the concentrations
measured in our study. The shape of the dose-response rela-
tionship of PFOA concentration with preeclampsia may be
nonlinear, with effects only observable at higher exposure
concentrations than those present in our study. However, dif-
ferences in exposure magnitude cannot explain the lack of
statistically significant association between PFOS and pre-
eclampsia found in our study, because the median PFOS
concentration in the previous study was approximately equal
to ours (22). The plasma concentrations of PFOA, PFNA,
PFDA, PFUnDA, PFHxS, and PFOS measured in our study
were similar to serum concentrations measured in women in
Norway in 2007 (12) and women in California in 2009 (40).
PFOS and PFOA concentrations were similar to those re-
ported in a sample of US adult female blood donors in 2006,
whereas PFNA and PFHxS concentrations in our study were
somewhat lower (41).
Our determination of preeclampsia was validated through
review of antenatal medical records, whereas previous studies
used self-reported preeclampsia (22, 39). The positive predic-
tive value of self-reported preeclampsia in a recent systematic
review was 50%–60% (42). The use of medical records to
validate the diagnosis may have reduced outcome misclassi-
fication in our study, possibly through the exclusion of other
hypertensive disorders of pregnancy.
Our study was restricted to nulliparous women, who have a
higher risk of preeclampsia than do parous women (43).
Women who develop preeclampsia in their second or later
pregnancies may have a different underlying set of risk
factors than nulliparous women. Approximately half of the
women in the previous studies (22, 39) were nulliparous.
The association between midpregnancy PFAS plasma con-
centrations and preeclampsia may differ between nulliparous
and parous women. Our restriction to nulliparous women
also ensured that measured PFAS concentrations did not re-
flect recent declines in body burden due to previous preg-
nancy and lactation (27, 44, 45).
We observed an inverse association between PFUnDA and
preeclampsia. We are not aware of any previous studies that
have evaluated this association. There are several possible ex-
planations for this finding, which may result from chance,
causality, confounding, or pharmacokinetics. One possible
explanation for the inverse association between PFUnDA
and preeclampsia may be the mediation of HDL cholesterol.
In a separate study within the MoBa cohort, all 7 PFAS stud-
ied were positively associated with HDL cholesterol levels at
midpregnancy, and PFUnDA showed the strongest associa-
tion with HDL (46). As higher levels of HDL are considered
protective against cardiovascular disease (47) and low HDL
cholesterol levels during pregnancy have been associated
with increased risk of preeclampsia (48), it is possible that
Table 3. Spearman Correlation Coefficients Between Plasma Concentrations of Perfluoroalkyl Substancesa in
Subjects in a Subcohort of the Norwegian Mother and Child Cohort Study, 2003–2007
PFOA PFNA PFDA PFUnDA PFHxS PFHpS PFOS
PFOA 0.61 0.45 0.31 0.54 0.53 0.64
PFNA 0.75 0.51 0.45 0.31 0.42
PFDA 0.54 0.27 0.18 0.25




Abbreviations: PFDA, perfluorodecanoic acid; PFHpS, perfluoroheptane sulfonate; PFHxS, perfluorohexane
sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate;
PFUnDA, perfluoroundecanoic acid.
a The 7 perfluoroalkyl substances were those with concentrations that could be quantitated in more than 50% of
samples.
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Table 4. Hazard Ratios for Preeclampsia Onset Associated With Plasma Perfluoroalkyl Substance Concentrations












Quartile 1 0.32–2.11 1.00 Referent 1.00 Referent
Quartile 2 2.12–2.77 0.99 0.70, 1.42 1.03 0.70, 1.50
Quartile 3 2.77–3.56 0.93 0.65, 1.32 0.92 0.63, 1.35
Quartile 4 3.56–11.28 0.88 0.61, 1.25 1.01 0.69, 1.48
Per ln-unit 0.84 0.63, 1.13 0.89 0.65, 1.22
PFNA
Quartile 1 <LOQ–0.39 1.00 Referent 1.00 Referent
Quartile 2 0.39–0.54 0.85 0.60, 1.22 0.88 0.60, 1.30
Quartile 3 0.54–0.74 0.92 0.64, 1.31 1.04 0.71, 1.53
Quartile 4 0.74–3.54 0.80 0.56, 1.15 0.88 0.60, 1.29
Per ln-unit 0.84 0.66, 1.07 0.90 0.70, 1.16
PFDA
Below median <LOQ–0.10 1.00 Referent 1.00 Referent
At or above median 0.10–1.74 0.81 0.63, 1.05 0.88 0.67, 1.16
Per ln-unit 0.86 0.74, 1.00 0.88 0.75, 1.04
PFUnDA
Quartile 1 <LOQ–0.08 1.00 Referent 1.00 Referent
Quartile 2 0.08–0.17 0.55 0.38, 0.79 0.51 0.35, 0.76
Quartile 3 0.17–0.27 0.57 0.40, 0.82 0.60 0.41, 0.88
Quartile 4 0.27–1.01 0.49 0.34, 0.71 0.55 0.38, 0.81
Per ln-unit 0.76 0.65, 0.89 0.78 0.66, 0.92
PFHxS
Quartile 1 <LOQ–0.49 1.00 Referent 1.00 Referent
Quartile 2 0.49–0.69 0.94 0.66, 1.34 0.86 0.59, 1.26
Quartile 3 0.69–0.95 1.00 0.70, 1.42 1.01 0.69, 1.49
Quartile 4 0.95–11.47 0.84 0.59, 1.19 0.93 0.64, 1.36
Per ln-unit 0.86 0.70, 1.06 0.91 0.72, 1.14
PFHpS
Quartile 1 <LOQ–0.09 1.00 Referent 1.00 Referent
Quartile 2 0.09–0.15 1.22 0.85, 1.74 1.30 0.88, 1.92
Quartile 3 0.15–0.22 1.01 0.71, 1.45 1.01 0.69, 1.48
Quartile 4 0.22–1.19 1.04 0.73, 1.48 1.12 0.77, 1.63
Per ln-unit 1.01 0.85, 1.20 1.03 0.86, 1.24
PFOS
Quartile 1 1.44–9.66 1.00 Referent 1.00 Referent
Quartile 2 9.67–12.79 1.18 0.82, 1.68 1.12 0.76, 1.65
Quartile 3 12.80–16.91 0.85 0.59, 1.21 0.88 0.60, 1.29
Quartile 4 16.91–56.61 1.08 0.75, 1.53 1.09 0.75, 1.58
Per ln-unit 1.08 0.82, 1.42 1.13 0.84, 1.52
Abbreviations: CI, confidence interval; HR, hazard ratio; LOQ, limit of quantification; PFDA, perfluorodecanoic acid;
PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFHpS,
perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFUnDA, perfluoroundecanoic acid.
a A total of 466 women developed preeclampsia.
b Adjusted for maternal age, prepregnancy body mass index (weight (kg)/height (m)2), education completed, and
smoking during pregnancy.
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Figure 1. Adjusted dose-response relationships between plasma concentrations of perfluoroalkyl substances at midpregnancy and the
natural-log–transformed odds ratio for preeclampsia using restricted cubic spline functions among 976 pregnant women enrolled in the Norwegian
Mother and Child Cohort Study, 2003–2007. Odds ratios were adjusted for maternal age, prepregnancy body mass index (weight (kg)/height (m)2),
education completed, and smoking during pregnancy. Restricted cubic spline functions have 5 knots at the 5th, 25th, 50th, 75th, and 95th percent-
iles, with the exception of PFDA, which has only 4 knots at the 25th, 50th, 75th, and 95th percentiles. The horizontal line denotes an odds ratio of 1,
the vertical line denotes the median of the observed distribution, and observed values are indicated by dots near the x-axis. PFDA, perfluorodeca-
noic acid; PFHpS, perfluoroheptane sulfonate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid;
PFOS, perfluorooctane sulfonate; PFUnDA, perfluoroundecanoic acid.
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an environmental factor leading to increasedHDL levels could
in fact reduce the risk of preeclampsia. Adjustment for HDL
produced no meaningful change in the estimated association
between PFUnDA and preeclampsia. However, if the associ-
ation between PFUnDA and preeclampsia were mediated
by HDL, then adjustment for HDL might produce estimates
that were biased or difficult to interpret (49, 50). Moreover,
it is unknown whether the previously observed association
between PFAS and HDL in pregnant women is causal or the
result of unmeasured confounding or pharmacokinetics.
Strengths of this study include the use of a validated diag-
nosis of preeclampsia, which serves to reduce outcome mis-
classification, and the use of a highly sensitive assay for
PFAS, which allowed for the quantification of several PFAS
that have not been studied extensively. However, our ability
to interpret the lack of association between concentrations of
these infrequently studied compounds and preeclampsia was
restricted by the fact that we found limited variation in expo-
sure concentration of these compounds.
In contrast to previous studies (22, 39), we were able to di-
rectly measure PFAS in plasma samples takenmidpregnancy,
before the onset of preeclampsia. However, the possibility re-
mains that an asymptomatic stage of the disease may already
be present at midpregnancy. If this hypothetical presymptom-
atic stagewere to alter kidney function, it could also influence
excretion and plasma concentrations of PFAS. Adjustment
for plasma creatinine or cystatin C levels did not affect our
results, which suggests that the estimates were not confounded
by measurably impaired kidney function. We cannot rule out
the possibility of bias due to confounding by an unmeasured
variable.
As previously noted, the participation rate in MoBa was
39% of eligible women. Selection bias may have influenced
the results of our study in unpredictable ways. For example, if
unmeasured variables were related to both exposure and se-
lection into the study or to both selection and the outcome,
bias could result. However, we are unaware of any probable
strong confounders that were unmeasured in this study.
Our preeclampsia case definition excluded pregnancies
without available antenatal medical records or for whom
the absence of hypertension before 20 weeks of gestation
could not be established. Preeclampsia superimposed on
chronic hypertension may have different associations with
PFAS than new-onset preeclampsia, but our study did not
evaluate superimposed preeclampsia. Our study did not cap-
ture women who only had recorded signs of preeclampsia in
the hospital (approximately 20% of all validated cases);
therefore, our study results may not be generalizable to all
cases. Another potential limitation of our study may be the
lower median BMI in this population as compared with US
populations. Only 11% of participants had a BMI of 30 or
greater, whereas 32% of US women aged 20–39 years have
a BMI in this range (51). This difference may limit general-
izability of these findings to US populations.
Overall, we did not observe any strongly positive associa-
tions between plasma PFAS concentration at midpregnancy
and preeclampsia among nulliparous women. Our results
suggest that examining the potential health effects of a longer
list of PFAS may be worthwhile. Further research should ex-
amine whether the observed inverse association between
PFUnDA and preeclampsia is present in other populations,
and if so, investigate mechanisms that may underlie this
association.
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